NovaBridge Biosciences (NBP) FCF Margin (2020)
NovaBridge Biosciences (NBP) posted quarterly FCF Margin of 5637.19% for Q4 2020.
Powered by 
Analysis
NovaBridge Biosciences (NBP) FCF Margin (2020) Analysis & Trends
NovaBridge Biosciences (NBP) has reported FCF Margin for 1 consecutive years, with 5637.19% the latest figure, recorded in Q4 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 70.82% |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -22.35% |
| 10 | NovaBridge Biosciences | 199.33 Mn | 199.33 Mn | - | - |